Thus, it is more prudent to combine Cav-1-targeting agents with antibodies against tumor specific antigens, such as EGFR, HER2, and mucins, etc. On the other hand, combining Cav-1 silencing agents with glycolysis inhibitors to prevent glycolytic activation in tumor stroma may also avoid the risk of fueling cancer cell growth. The gene discussed is EGFR; the disease is neoplasm.